Davidson Matt

Davidson Matt is listed in filings as Chief Development Officer at Adial Pharmaceuticals, Inc.. This profile follows SEC Form 4 activity through Jun 16, 2026, including 6 public disclosures. Recent filings connect the profile to Adial Pharmaceuticals, Inc. (ADIL). The current snapshot covers public activity from Jun 16, 2026. Reported amounts are shown as $671.7K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.